London start-up Lindus Health announces trials for insomina, tinnitus and short-sightedness

By Liza Laws

- Last updated on GMT

Team at Lindus Health
Team at Lindus Health

Related tags tinnitus Insomnia Sleep short-sightedness Clinical trials Research patient engagement

A London-based start-up that says clinical trials are ‘the biggest bottleneck to improving human health’ is launching a number of ‘breakthrough’ treatments for conditions including tinnitus, insomnia and progressive childhood short-sightedness.

Lindus Health will use its technology platform and machine learning to manage trials from start to finish aiming to help treatments reach patients quickly in a bid to improve and extend lives.

The news comes as the company reveals it has to date raised $6million from investors, including from Firstminute, Seedcamp and Peter Thiel, PayPal co-founder and the first outside investor in Facebook, to accelerate their use of machine learning and data science to revolutionise clinical trials. 

Lindus Health is also announcing that it has received an Innovate UK Smart Grant, part of UK Research and Innovation (UKRI), worth just under £500,000, with their work in machine learning and data science described by UKRI assessors as a ‘​​hugely valuable and game-changing project’.

The company says its technology speeds up the time it takes to approve treatments and get them to market, with their trials to date having been completed three times more quickly than the old-fashioned industry standard.

Lindus has delivered more than 80 trials for treatments across the US, UK and Europe and will next be working with healthcare company, Pharmanovia, to evaluate the safety and efficacy of a treatment for patients with severe insomnia in a real-world setting. It will use digital technology to find hard-to-reach insomnia patients.

Working with Oto, a provider of digital tinnitus programs, the company will run a trial for 200 people evaluating their digital tinnitus solution against in-person therapy.

Additionally, it is partnering with Berlin-based start-up, Dopavision, to trial the MyopiaX treatment for children affected by progressive short sightedness. This aims to increase dopamine levels in the retina to slow the progression of the condition. 

This year, Lindus is also launching a trial aimed at treating and reversing type 2 diabetes with George Medicines.

Launched in 2021 by Michael Young and Meri Beckwith, Lindus Health has already worked with 20,000 patients to find new treatments for chronic conditions.

Co-founder of Lindus Health, Michael Young, said: “Clinical trials are the biggest bottleneck to improving human health. We’re working with high-growth companies developing the next wave of breakthrough treatments to accelerate the clinical trials process. 

“It’s fantastic to be working with the Government and industry pioneers to revolutionise clinical trials to deliver treatments to benefit patients more quickly.

“From monitoring trial data in real time to using machine learning to predict trial outcomes and make improvements to trial designs in advance, we want to simplify and accelerate the trials process and put patients first.” 

Related news

Show more